Intranasal ipratropium in the treatment of vasomotor rhinitis.

Abstract

Ipratropium administered in the form of a nasal spray was compared with placebo in 30 patients with vasomotor rhinitis in a double-blind cross-over trial. There was a significant reduction in nasal hypersecretion during ipratropium treatment, but no effect on nasal blockage, sneezing or tickling. On the whole, 20 patients (66.7%) considered ipratropium worth using. 11 patients had mild side- effects, mainly nasal irritation, during ipratropium treatment and 7 with placebo. A therapeutical trial with ipratropium is appropriate in the management of severe rhinorrhoea in patients with vasomotor rhinitis.

• Authors: K Jokinen, P Sipilä
• Journal: Rhinology (Rhinology) Vol. 21 Issue 4 Pg. 341-5 (Dec 1983) ISSN: 0300-0729 [Print] Netherlands
• PMID: 6229864 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Atropine Derivatives
• Ipratropium

Topics

• Administration, Intranasal
• Adolescent
• Adult
• Aged
• Atropine Derivatives (administration & dosage)
• Clinical Trials as Topic
• Double-Blind Method
• Humans
• Ipratropium (administration & dosage)
• Middle Aged
• Nasal Mucosa (metabolism)
• Rhinitis, Vasomotor (drug therapy, physiopathology)
• Sneezing (drug effects)